Paxlovid, COVID

Paxlovid does not significantly cut COVID hospitalization in older vaccinated adults, study finds
The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to new research by UCLA doctors. The findings, published Thursday in a research letter in the Journal of the American Medical Association,
Data suggest Paxlovid doesn't reduce severe COVID in older, vaccinated adults
The authors compared outcomes among adults just under 70 years who were not prescribed Paxlovid to those who were given the antiviral. The authors identified 1,620,884 Ontarians aged 65 to 74 years during the study period; most (87.5%) received at least 2 COVID-19 vaccines.
Paxlovid shows no clear benefit in preventing hospitalization, death among vaccinated seniors
COVID-19 treatment called into question after major study In a nutshell A major study of 1.6 million seniors found that Paxlovid, while widely prescribed, did not significantly reduce COVID-19 hospitalizations or deaths in vaccinated older adults When Paxlovid prescriptions more than doubled for patients over 70,
Study: No large benefit from Paxlovid among COVID-vaccinated older adults
Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as previously thought, according to research published in JAMA.
Paxlovid shows limited benefit in older adults vaccinated against COVID-19, new research reveals
A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven efficacy in unvaccinated populations.
Paxlovid Is Less Effective In Older Vaccinated Covid Patients, Study Shows
Covid hospitalizations were not significantly reduced when adults used the antiviral pill, researchers find. Also, a nationwide study suggests estrogen may play a role in long covid, putting women at a higher risk.
Paxlovid May Not Significantly Benefit Vaccinated Seniors, Study Says
In the latest study, however, researchers report that taking Paxlovid may not provide as much benefit as doctors originally thought—particularly for older people who are vaccinated. In a research letter published in JAMA on Feb.
News Medical on MSN3d
Paxlovid's promise fades: Vaccinated seniors see minimal COVID-19 protection
Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.